Literature DB >> 29566843

The Importance of Model Structure in the Cost-Effectiveness Analysis of Primary Care Interventions for the Management of Hypertension.

Maria Cristina Peñaloza-Ramos1, Sue Jowett2, Andrew John Sutton3, Richard J McManus4, Pelham Barton2.   

Abstract

BACKGROUND: Management of hypertension can lead to significant reductions in blood pressure, thereby reducing the risk of cardiovascular disease. Modeling the course of cardiovascular disease is not without complications, and uncertainty surrounding the structure of a model will almost always arise once a choice of a model structure is defined.
OBJECTIVES: To provide a practical illustration of the impact on the results of cost-effectiveness of changing or adapting model structures in a previously published cost-utility analysis of a primary care intervention for the management of hypertension Targets and Self-Management for the Control of Blood Pressure in Stroke and at Risk Groups (TASMIN-SR).
METHODS: The case study assessed the structural uncertainty arising from model structure and from the exclusion of secondary events. Four alternative model structures were implemented. Long-term cost-effectiveness was estimated and the results compared with those from the TASMIN-SR model.
RESULTS: The main cost-effectiveness results obtained in the TASMIN-SR study did not change with the implementation of alternative model structures. Choice of model type was limited to a cohort Markov model, and because of the lack of epidemiological data, only model 4 captured structural uncertainty arising from the exclusion of secondary events in the case study model.
CONCLUSIONS: The results of this study indicate that the main conclusions drawn from the TASMIN-SR model of cost-effectiveness were robust to changes in model structure and the inclusion of secondary events. Even though one of the models produced results that were different to those of TASMIN-SR, the fact that the main conclusions were identical suggests that a more parsimonious model may have sufficed.
Copyright © 2018 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiovascular disease; decision-analytic modeling; hypertension; modeling; structural uncertainty

Mesh:

Substances:

Year:  2017        PMID: 29566843     DOI: 10.1016/j.jval.2017.03.003

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  2 in total

Review 1.  Are PCSK9 Inhibitors Cost Effective?

Authors:  Max J Korman; Kjetil Retterstøl; Ivar Sønbø Kristiansen; Torbjørn Wisløff
Journal:  Pharmacoeconomics       Date:  2018-09       Impact factor: 4.981

Review 2.  Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness.

Authors:  Clara Marquina; Ella Zomer; Sandra Vargas-Torres; Sophia Zoungas; Richard Ofori-Asenso; Danny Liew; Zanfina Ademi
Journal:  Pharmacoeconomics       Date:  2020-10       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.